Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Revolution Medicines has begun treating patients in RASolve 308, a global Phase 3 trial of zoldonrasib plus pembrolizumab and chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC. The randomized, double-blind study uses progression-free survival as its primary endpoint, with overall survival, response rate, and duration of response among key secondary endpoints.
Key figures
- Drug Name
- zoldonrasib
- Phase Of Trial
- Phase 3
- Trial nct
- NCT07777822
- Trial name
- RASolve 308
- Primary endpoint
- progression-free survival
- Ras g12d share of nsclc
- approximately 4%
- Est annual us ras g12d patients
- 61000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.